Echeverria v. Johnson
37 Cal. App. 5th 292
Cal. Ct. App. 5th2019Background
- Plaintiff Eva Echeverria used Johnson's Baby Powder (perineal application) from 1965–2016 and developed high‑grade serous ovarian cancer in 2007; Johnson & Johnson (J&J) manufactured the product until 1967, thereafter JJCI (a J&J subsidiary) manufactured it.
- Plaintiff sued J&J and JJCI for negligent failure to warn; jury awarded large compensatory and punitive damages; trial court granted JNOV as to both defendants and a new trial; both sides appealed.
- Key factual disputes at trial: general causation (does genital talc cause ovarian cancer?) and specific causation (did defendants’ product cause Echeverria’s cancer).
- Plaintiff presented experts on general causation (toxicology, epidemiology) and specific causation (gynecologic oncologist who did a differential diagnosis) and pathology showing talc particles in tissue; defendants presented experts disputing causation and the strength of the epidemiology.
- Documentary evidence showed JJCI monitored studies, participated in industry responses, and sought to defend talc; only limited pre‑1967 material (a 1964 internal memo) was offered against J&J.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Duty and breach — J&J (parent that ceased manufacturing in 1967) | J&J had/should have had notice pre‑1967 and/or remained liable after transfer | J&J ceased manufacture in 1967 and had no knowledge of ovarian‑talc risk then; no continuing duty to warn for JJCI’s product | No substantial evidence J&J had or should have had knowledge by 1967 or legal theory to impose post‑1967 duty; JNOV for J&J affirmed |
| Duty and breach — JJCI (manufacturer during relevant period) | JJCI knew or reasonably should have known by 2007 of talc‑ovarian cancer risk and breached duty to warn | Scientific evidence was inconclusive; reasonable manufacturer would not have had to warn | Sufficient evidence that by 2007 JJCI had enough studies/evidence to permit jury to find breach; JNOV as to liability reversed |
| Specific causation (did talc cause Echeverria’s cancer?) | Plaintiff’s treating oncologist, pathology and epidemiology support specific causation via differential diagnosis, tissue talc, and studies (some RR >2) | Experts say epidemiology is weak/inconsistent; alternative causes and idiopathic origin not ruled out | Jury had substantial evidence to find specific causation; trial court’s JNOV on liability for JJCI reversed, but court properly weighed conflicts in granting new trial |
| Punitive damages against JJCI | Plaintiff: JJCI acted with conscious/disregard by defending and concealing risks | JJCI: conduct was defense of inconclusive science; no clear and convincing proof of malice | No clear and convincing evidence of malice or despicable conduct; JNOV for punitive damages against JJCI affirmed |
Key Cases Cited
- Sargon Enterprises, Inc. v. University of Southern California, 55 Cal.4th 747 (Cal. 2012) (standards for admissibility of expert opinion)
- Webb v. Special Electric Co., Inc., 63 Cal.4th 167 (Cal. 2016) (standard for reviewing JNOV)
- Valentine v. Baxter Healthcare Corp., 68 Cal.App.4th 1467 (Cal. Ct. App. 1998) (distinguishing negligent failure‑to‑warn from strict liability warning duties)
- Carlin v. Superior Court, 13 Cal.4th 1104 (Cal. 1996) (manufacturer duty to warn defined)
- T.H. v. Novartis Pharmaceuticals Corp., 4 Cal.5th 145 (Cal. 2017) (prevailing scientific knowledge and failure‑to‑warn analysis for pharmaceuticals)
- Daubert v. Merrell Dow Pharmaceuticals, Inc. (Daubert II), 43 F.3d 1311 (9th Cir. 1995) (role of epidemiology and RR thresholds in specific causation)
- Cooper v. Takeda Pharmaceuticals America, Inc., 239 Cal.App.4th 555 (Cal. Ct. App. 2015) (applying Daubert reasoning to epidemiology and specific causation)
- Lane v. Hughes Aircraft Co., 22 Cal.4th 405 (Cal. 2000) (different standards on appeal for JNOV vs. new trial)
- Shade Foods, Inc. v. Innovative Products Sales & Marketing, Inc., 78 Cal.App.4th 847 (Cal. Ct. App. 2000) (clear‑and‑convincing standard for punitive damages review)